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sponders and 0.785 (0.012) for nonresponders. CONCLUSIONS:Utility values can be
derived from condition-specificmeasures such as the QLQ-C30. Our analyses dem-
onstrate that the presence of CS and splenomegaly in patients with myelofibrosis
results in lower utility values.
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OBJECTIVES: To examine published evidence describing preference-based utility
weights for hepatocellular carcinoma (HCC) in order to inform health gains within
future economic evaluations in HCC.METHODS: The systematic review of utilities
reported in the technology appraisal submission to the National Institute for
Health and Clinical Excellence for sorafenib for advanced HCC (TA189) was up-
dated. Studies that reported preference-based utility weights for HCC indexed in
the EMBASE.comdatabasewere searched for and included. Bibliographic searching
of included studies was conducted to retrieve any additional, relevant studies.
Health technology assessments (HTA) submissions reporting relevant data were
also included. RESULTS: Forty-eight published studies (with 13 primary studies
reporting unique data) and two HTA submissions met the inclusion criteria. Four
studies directly measured utility or quality of life (QoL) used to derive utility values
of patients with HCC; instruments such as the EQ-5D and/or Health Utilities Index
Mark Three, or free-standing techniques such as standard gamble or time trade-off
(TTO) were employed. The two HTA submissions reported utility weights associ-
ated with HCC derived by mapping FACT-HEP clinical trial data to TTO utility
values. One cross-study comparison of estimates highlighted that patientswithout
the disease consider the utility associated with HCC to be lower (0.2-0.5) than
patients with HCC (0.6-0.8). Utility weights were broadly similar across studies
which directlymeasured utility frompatients with HCC orwhichmappedQoL data
from patients with HCC to utility weights, despite differences in study country and
utility instrument. Four studies measured QoL using the SF-36 or FACT-G; all dem-
onstrated that scoreswere lower for the general health perception domain than the
other domains. CONCLUSIONS: Consistent with trends documented elsewhere in
the literature, utility weights derived from patients with disease were generally
higher than those derived from individuals without. There exists little variation in
utility score by instrument applied.
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OBJECTIVES: Preference-based scoring approaches to measuring health-related
quality of life (HRQL) in cancer are proliferating. The objective of this study was to
compare preference-based scores estimated by scoring functions for the generic
EQ-5D and cancer-specific Functional Assessment of Cancer Therapy (FACT) in
terms of differences between algorithms and cancer subtype.METHODS: Second-
ary data analysis of patients with advanced cancer (breast, brain, colorectum,
hepatobiliary system, lung, and ovary; n41 to 49 for each subgroup) was con-
ducted. Each patient completed both the EQ-5D and FACT; scores were calculated
using scoring functions for EQ-5D (Dolan, Shaw et al), an EQ-5D mapping function
(Cheng et al) and FACT (Kind/Macran, Dobrez et al). ECOG performance status rated
by physician was used to stratify patients by severity. The relative statistical effi-
ciency (RE) of each algorithm to capture differences in severitywas compared using
ratios of F-statistics. RESULTS: The rank order of the scores generated by different
scoring functions were fairly consistent across cancer subtype, with the lowest
mean scores derived from FACT by Kind/Macran (0.52, hepatobiliary, to 0.57, colo-
rectal), and highest mean scores using scoring by Dobrez et al (0.80, hepatobiliary,
to 0.85, brain). Within each scoring function, no statistically significant differences
in mean scores were found across cancer types. The Dolan algorithm resulted in
largest differences inmean scores by severity (ECOG) grades for brain, breast, colo-
rectal and ovarian cancer. The FACT UK societal algorithm by Kind et al had the
largest RE for 3 of the cancers (breast, hepatobiliary, and ovarian cancer).
CONCLUSIONS: Each scoring approach produced different preference-based
scores within and across subtype of cancer; extrapolating from ability to discrim-
inate levels of severity EQ-5D scoring functions generally provided scores that
would extrapolate to larger QALY benefits compared to FACT-based approaches.
No statistically significant differences in the utility scoreswere observed across the
cancer types, but some differences could be considered meaningful; lack of power
was a limitation.
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OBJECTIVES: Preference-based measures have been derived from various descrip-
tive HRQOLmeasures. A general 2-stagemethod has evolved: 1) an item from each
domain of the HRQOL measure is selected to form a health state classification
system (HSCS), and 2) a sample of health states is valued and an algorithm derived
for estimating the utility of all possible health states. The outputs of these two
stages represent a MAUI. Our aim was to adapt the first stage for the widely-used
cancer-specific QLQ-C30, and apply it to a large, heterogeneous, international da-
taset as the first step in developing an internationally-valid cancer-specific MAUI.
METHODS: Secondary analyses were conducted on a pooled dataset comprising
QLQ-C30 responses plus demographic and clinical data from 2616 patients from
eight countries, over 14 cancer sites, all stages, and all common cancer treatments.
The established domain structure of the QLQ-C30 (physical, role, emotional, social
and cognitive functioning, plus several symptoms) formed the underlying concep-
tual model for the MAUI. Generalisability of the conceptual model across cancer
sites was tested with multi-group CFA. Items within each domain were then sub-
jected to statistical scrutiny, including Rasch analysis for domains with sufficient
items. RESULTS: CFA results supported the proposed conceptual model and its
generalisability across cancer sites. Two items exhibited floor effects (75% obser-
vations at lowest score), none exhibited misfit to the Rasch model, one exhibited
disordered item response thresholds, and two exhibited differential item function
by cancer site. These results, along with results for responsiveness and qualitative
patient input (analyses underway) will be presented. CONCLUSIONS: The next
stage of this research will obtain valuations for a range of health states defined by
the HSCS from general population samples in various countries. The ability to
determine a preference-based utility score from QLQ-C30 responses will facilitate
cost-utility analysis in cancer trials which use the QLQ-C30.
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OBJECTIVES: Although less than 5% of breast cancers occur among women under
45, the impact on health-related quality of life (HRQOL) may be significant since
these cancers strike earlier in a woman’s life. This study addresses a gap in the
literature on the health utility impacts of breast cancer among U.S. women ages
18-44. METHODS: Self-reported cancer history and HRQOL for US women were
measured from the 2009 and 2010 Behavioral Risk Factor Surveillance System
(BRFSS), a nationally representative population-based survey. BRFSS did not in-
clude preference-based measures of HRQOL, so Jia et al.’s (2011) mapping of
HealthyDays (HRQOL-4) to the EQ-5D and Shawet al.’s (2005) estimates of US utility
weights were applied. The difference in health utilities and in Healthy Days (non-
preference-weighted) was assessed using multivariate regression controlling for
sociodemographics and major health risk factors. RESULTS: A total of 343 of
133,294 women ages 18-44 in the 2009-2010 BRFSS reported breast cancer. Unad-
justed mean utility was .073 lower (p0.01) among women with a history of breast
cancer. Among women ages 45 and older, the difference was much smaller, 0.008
(p0.01). Adjusting for sociodemographic factors and years since diagnosis, the
decrease in health utility for breast cancer was 0.090 lower (p0.01) for women
18-44; similar analysis of women ages 45 and older with breast cancer showed an
estimated impact of 0.017 (p0.01). Mean unhealthy days (physical, mental, or
activity limitations) were also significantly lower in younger women with breast
cancer. CONCLUSIONS: Although women 18-44 are a small fraction of breast can-
cer cases, the health utility impact at the individual level is substantial. Although
the utility decrement is significant for women of all ages, the impact of breast
cancer is 5-6 times greater in younger women. Age-specific utility values of breast
cancer are critical for generating accurate results from cost-utility and modeling.
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OBJECTIVES: Patient choice is increasingly recognized as a key factor in medical
decision making process. This study aims to investigate preferences for adjuvant
chemotherapy among women with early stage breast cancer in Taiwan.
METHODS: Patient interviews were administered on women aged under 60 who
sought treatment for stage I or II stage breast cancer at the outpatient department
of two medical centers located in Taipei City, Taiwan. Five attributes of adjuvant
chemotherapy was identified as the key determinants when making choices: fre-
quency and administraton, length of treatment, cardiac toxicity, recurrence rate,
and out-of-pocket payments.Survey questionnaire was designed based upon dis-
crete choice experiments (DCEs). Preferences for 13 choice sets were elicited with
opt-out option included. In total, 104 respondents were recruited by the end of
2011. Multinomial logit model was used to assess the relative value of product
features and trade-off between attributes. Cluster analysis was used to Isolate
women groups who place differing importance on different features. RESULTS:
Descriptive statistics showed that most women were marred (77.2%) with mean
age of 48.0. About half of the women were ful-time employed (52.6%) and 35.1 of
them received years of education  16 years (35.1%). Prelimanary regression anal-
ysis indicated that women significantly preferred shorter length of treatment, no
cardiac toxicity, lower recurrence rate and lower out-of-pocket payment.
CONCLUSIONS: The authorities concerned should incorporate patients’ prefer-
ences into the existing decision making process when making reimbursement
decision.
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